	US 12,247,984 B2
	Generation of human allergen- and helminth-specific IgE monoclonal antibodies for diagnostic and therapeutic use
Scott A. Smith, White Bluff, TN (US)
Assigned to VANDERBILT UNIVERSITY, Nashville, TN (US)
Filed by Vanderbilt University, Nashville, TN (US)
Filed on Dec. 18, 2020, as Appl. No. 17/127,953.
Application 17/127,953 is a continuation of application No. 16/481,165, granted, now 10,908,168, previously published as PCT/US2018/015870, filed on Jan. 30, 2018.
Claims priority of provisional application 62/452,603, filed on Jan. 31, 2017.
Prior Publication US 2021/0382064 A1, Dec. 9, 2021
Int. Cl. A61K 39/395 (2006.01); A61K 39/35 (2006.01); A61K 45/06 (2006.01); C07K 16/16 (2006.01); C07K 16/18 (2006.01); G01N 33/53 (2006.01); G01N 33/68 (2006.01)

CPC G01N 33/686 (2013.01) [A61K 39/35 (2013.01); A61K 45/06 (2013.01); C07K 16/16 (2013.01); C07K 16/18 (2013.01); G01N 33/5308 (2013.01); C07K 2317/21 (2013.01); G01N 2333/43526 (2013.01); G01N 2333/43582 (2013.01)]

11 Claims

1. A method of treating a dust mite-related allergic reaction in a subject comprising delivering to said subject an IgG antibody or antibody fragment, wherein said antibody or antibody fragment comprises heavy chain CDR1 SEQ ID NO: 123, heavy chain CDR2 SEQ ID NO: 124, heavy chain CDR3 SEQ ID NO: 125, light chain CDR1 SEQ ID NO: 201, light chain CDR2 SEQ ID NO: 202, and light chain CDR3 SEQ ID NO: 203.